Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106557 | 0.86 | MIF (0.61) | MIFHPGDNOTUMTSHRKDM4E | |
| SCHEMBL1106568 | 0.84 | MIF (0.43) | MIFHPGDTSHRKDM4ELMNA | |
| SCHEMBL3082953 | 0.84 | MIF (0.59) | MIFHPGDNOTUMTSHRP2RX7 | |
| SCHEMBL3091423 | 0.84 | MIF (0.62) | MIFHPGDNOTUMTSHRP2RX7 | |
| SCHEMBL8278934 | 0.83 | MIF (0.58) | MIFHPGDNOTUMTSHRKDM4E | |
| SCHEMBL3087609 | 0.82 | MIF (0.55) | MIFHPGDNOTUMTSHR | |
| SCHEMBL3090082 | 0.82 | MIF (0.60) | MIFHPGDNOTUMP2RX7 | |
| SCHEMBL1106573 | 0.82 | HPGD (0.43) | MIFHPGDTSHRKDM4ELMNA | |
| SCHEMBL1106616 | 0.82 | MIF (0.56) | MIFHPGDNOTUMTSHRKDM4E | |
| SCHEMBL1106605 | 0.81 | HPGD (0.49) | MIFHPGDTSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MIF 997/4885HPGD 316/4885NOTUM 578/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MIF 997/4885HPGD 316/4885NOTUM 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.